Organs at risk in lung SBRT

F De Rose; D Franceschini; G Reggiori; A Stravato; P Navarria; A M Ascolese; S Tomatis; P Mancosu; M Scorsetti

doi:10.1016/j.ejmp.2017.04.010

Organs at risk in lung SBRT

Phys Med. 2017 Dec:44:131-138. doi: 10.1016/j.ejmp.2017.04.010. Epub 2017 Apr 19.

Authors

F De Rose¹, D Franceschini¹, G Reggiori¹, A Stravato², P Navarria¹, A M Ascolese¹, S Tomatis¹, P Mancosu¹, M Scorsetti³

Affiliations

¹ Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research Hospital, Milan, Italy.
² Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research Hospital, Milan, Italy. Electronic address: antonella.stravato@humanitas.it.
³ Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research Hospital, Milan, Italy; Depart ment of Biomedical Sciences, Humanitas University, Milan, Italy.

PMID: 28433508
DOI: 10.1016/j.ejmp.2017.04.010

Abstract

Lung stereotactic body radiotherapy (SBRT) is an accurate and precise technique to treat lung tumors with high 'ablative' doses. Given the encouraging data in terms of local control and toxicity profile, SBRT has currently become a treatment option for both early stage lung cancer and lung oligometastatic disease in patients who are medically inoperable or refuse surgical resection. Dose-adapted fractionation schedules and ongoing prospective trials should provide further evidence of SBRT safety trying to reduce toxicities and complications. In this heterogeneous scenario, a non-systematic review of dose constraints for lung SBRT was performed, including the main organs at risk in the thorax.

Keywords: Dose constraints; Lung SBRT; Organs at risk.

Publication types

Review
Systematic Review

MeSH terms

Humans
Lung Neoplasms / radiotherapy*
Organs at Risk / radiation effects*
Radiosurgery / adverse effects*